Here are five takeaways:
1. The results demonstrate a single administration of PREOB has positive effects on pain and osteoporosis blood markers.
2. The trial currently involves seven patients who don’t respond to anti-osteoporotic therapy.
3. The patients experienced more than 40 percent decreases in pain. In comparison, patients receiving anabolic agent teriparatide saw a 30 percent decrease in pain.
4. Researchers found a decrease of more than 25 percent of bone resorption markers in an early phase of the 12-month follow-up.
5. The preliminary results suggest a single administration of PREOB stimulates bone remodeling, with a favorable bone formation-to-resorption ratio.
More articles on devices:
SpineCraft shows 4 technologies at AANS/CNS Spine Summit
Carestream introduces cone beam CT system for orthopedic practitioners — 4 insights
Anika’s CINGAL receives CE Mark approval — 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
